| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
115,049,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Annexon is a clinical-stage biopharmaceutical company developing a class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Co. is developing a pipeline of product candidates designed to block the activity of C1q and the entire classical complement pathway for a range of complement-mediated diseases. Co.'s pipeline includes three clinical-stage assets across three therapeutic franchises: autoimmune, neurodegenration and ophtamology. Co. its developing its primary candidate, ANX005.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
2,363,843 |
2,376,188 |
2,380,303 |
2,405,903 |
| Total Buy Value |
$8,825,493 |
$8,856,643 |
$8,866,766 |
$9,006,282 |
| Total People Bought |
3 |
3 |
3 |
3 |
| Total Buy Transactions |
8 |
11 |
12 |
20 |
| Total Shares Sold |
0 |
3,086 |
46,012 |
93,312 |
| Total Sell Value |
$0 |
$7,987 |
$134,425 |
$421,027 |
| Total People Sold |
0 |
3 |
6 |
6 |
| Total Sell Transactions |
0 |
3 |
12 |
27 |
| End Date |
2025-10-02 |
2025-07-01 |
2024-12-31 |
2024-01-01 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Choi Jung |
|
– • – |
2025-12-01 |
4 |
B |
$4.19 |
$138,270 |
I/I |
33,000 |
33,000 |
0.01 |
- |
|
| Carson William H. |
|
– • – |
2025-12-01 |
4 |
AB |
$4.47 |
$18,394 |
D/D |
4,115 |
50,290 |
|
- |
|
| Satter Muneer A |
|
– • – |
2025-11-21 |
4 |
B |
$4.28 |
$1,808,784 |
I/I |
422,613 |
9,728,637 |
0.01 |
- |
|
| Satter Muneer A |
|
– • – |
2025-11-20 |
4 |
B |
$4.48 |
$1,792,000 |
I/I |
400,000 |
9,306,024 |
0.01 |
- |
|
| Satter Muneer A |
|
– • – |
2025-11-19 |
4 |
B |
$3.94 |
$1,970,000 |
I/I |
500,000 |
8,906,024 |
0.01 |
- |
|
| Satter Muneer A |
|
– • – |
2025-11-18 |
4 |
B |
$3.18 |
$1,590,000 |
I/I |
500,000 |
8,406,024 |
0.01 |
- |
|
| Satter Muneer A |
|
– • – |
2025-11-17 |
4 |
B |
$2.99 |
$1,495,000 |
I/I |
500,000 |
7,906,024 |
0.01 |
- |
|
| Carson William H. |
|
– • – |
2025-10-30 |
4 |
AB |
$3.17 |
$13,045 |
D/D |
4,115 |
46,175 |
|
- |
|
| Carson William H. |
|
– • – |
2025-09-30 |
4 |
AB |
$3.05 |
$12,551 |
D/D |
4,115 |
42,060 |
|
- |
|
| Carson William H. |
|
– • – |
2025-09-02 |
4 |
AB |
$2.09 |
$8,600 |
D/D |
4,115 |
37,945 |
|
- |
|
| Carson William H. |
|
– • – |
2025-07-30 |
4 |
AB |
$2.43 |
$9,999 |
D/D |
4,115 |
33,830 |
|
- |
|
| Overdorf Michael |
EVP & CHIEF BUSINESS OFFICER |
• – – |
2025-07-14 |
4 |
S |
$2.61 |
$2,226 |
D/D |
(853) |
130,689 |
|
- |
|
| Lew Jennifer |
EVP & CHIEF FINANCIAL OFFICER |
• – – |
2025-07-14 |
4 |
S |
$2.58 |
$2,882 |
D/D |
(1,117) |
121,616 |
|
- |
|
| Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
• – – |
2025-07-14 |
4 |
S |
$2.58 |
$2,879 |
D/D |
(1,116) |
105,084 |
|
- |
|
| Carson William H. |
|
– • – |
2025-06-30 |
4 |
AB |
$2.46 |
$10,123 |
D/D |
4,115 |
29,715 |
|
- |
|
| Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
• – – |
2025-02-18 |
4 |
S |
$2.91 |
$24,284 |
D/D |
(8,345) |
61,237 |
|
- |
|
| Dananberg Jamie |
CHIEF MEDICAL OFFICER |
• – – |
2025-02-18 |
4 |
S |
$2.96 |
$16,342 |
D/D |
(5,521) |
33,479 |
|
- |
|
| Lew Jennifer |
EVP & CHIEF FINANCIAL OFFICER |
• – – |
2025-02-18 |
4 |
S |
$2.92 |
$20,183 |
D/D |
(6,912) |
77,770 |
|
- |
|
| Overdorf Michael |
EVP & CHIEF BUSINESS OFFICER |
• – – |
2025-02-18 |
4 |
S |
$2.95 |
$19,523 |
D/D |
(6,618) |
86,579 |
|
- |
|
| Artis Dean Richard |
EVP & CHIEF SCIENTIFIC OFFICER |
• – – |
2025-02-18 |
4 |
S |
$2.97 |
$16,380 |
D/D |
(5,515) |
83,814 |
|
- |
|
| Overdorf Michael |
EVP & CHIEF BUSINESS OFFICER |
• – – |
2025-02-13 |
4 |
S |
$2.99 |
$4,261 |
D/D |
(1,425) |
93,197 |
|
- |
|
| Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
• – – |
2025-02-13 |
4 |
S |
$2.99 |
$5,331 |
D/D |
(1,783) |
69,582 |
|
- |
|
| Lew Jennifer |
EVP & CHIEF FINANCIAL OFFICER |
• – – |
2025-02-13 |
4 |
S |
$2.98 |
$5,322 |
D/D |
(1,786) |
84,682 |
|
- |
|
| Love Douglas |
PRESIDENT AND CEO |
• • – |
2025-02-13 |
4 |
S |
$2.95 |
$14,812 |
D/D |
(5,021) |
351,554 |
|
- |
|
| Love Douglas |
PRESIDENT AND CEO |
• • – |
2025-01-06 |
4 |
OE |
$1.41 |
$53,556 |
D/D |
37,994 |
356,575 |
|
- |
|
130 Records found
|
|
Page 1 of 6 |
|
|
